Our Firm is representing a number of GranuFlo lawsuit clients who allegedly suffered serious cardiovascular events due to the use of these products. Many of the allegations put forth in theses lawsuits echo those included in the Louisiana filing.
New York, NY (PRWEB) June 30, 2014
GranuFlo lawsuits (http://www.thegranuflolawsuit.com/) stemming from the 2012 GranuFlo and NaturaLyte dialysis concentrate recall continue to mount in courts around the U.S., Bernstein Liebhard LLP reports. According to an article published by the Associated Press on June 28th, the Louisiana Attorney General’s Office has filed a complaint against Fresenius Medical Care alleging that its sale of the two products prior to the 2012 GranuFlo recall defrauded dialysis clinics, physicians, the state and its residents.* According to court documents, the complaint is one of hundreds of GranuFlo recall claims filed against Fresenius, the majority of which are pending in a federal multidistrict litigation underway in U.S. District Court, District of Massachusetts. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)
“Our Firm is representing a number of GranuFlo lawsuit clients who allegedly suffered serious cardiovascular events due to the use of these products. Many of the allegations put forth in theses lawsuits echo those included in the Louisiana filing,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free GranuFlo lawsuit evaluations to dialysis patients who allegedly suffered cardiac arrest, heart attacks, stroke, sudden cardiac death or other side effects within 72 hours of a dialysis treatment involving the use of GranuFlo of NaturaLyte.
According to the Associated Press, the Louisiana GranuFlo lawsuit names Fresenius Medical Care, as well as nearly 100 dialysis clinics the company owns in the state, as defendants. Among other things, the complaint alleges that Fresenius knew as early as 2004 that inappropriate dosages of GranuFlo and NaturaLyte could elevate dialysis patients' bicarbonate levels and increase the risk of a heart attack, but did not issue a public notification about these risks until March 2012. The lawsuit seeks civil penalties of $5,000 per violation under Louisiana's Unfair Trade Practices and Consumer Protection Law, as well as any profits Fresenius earned from the sale of GranuFlo and NaturaLyte.*
Both GranuFlo and NaturaLyte are used to remove toxins from the blood during dialysis treatments. In March 2012, Fresenius issued an Urgent Product Notification for both products that warned of dosage issues that could cause dialysis patients to suffer serious and catastrophic heart side effects. The U.S. Food & Drug Administration (FDA) ultimately granted Class I recall status to the Urgent Product Notification, which indicates GranuFlo and NaturaLyte posed a risk of serious injury and death.
According to court documents, more than 1,860 GranuFlo lawsuits are now pending in the litigation underway in the District of Massachusetts. Additional claims have also been filed on the state level in the Massachusetts’ Middlesex County Superior Court. (In re: Consolidated Fresenius Cases, No. MICV2013-03400-O). All of the lawsuits similarly allege that Fresenius failed to provide adequate warnings regarding the risks associated with GranuFlo and NaturaLyte, and that the company continued to aggressively market the products even once it became aware of those risks.
Dialysis patients who allegedly suffered a heart attack, stroke, or other serious cardiovascular event within 72 hours of a dialysis treatment with GranuFlo or NaturaLyte may be eligible to file their own GranuFlo lawsuit. To learn more about the GranuFlo recall, please visit Bernstein Liebhard LLP’s website, or the Firm’s Facebook page: https://www.facebook.com/granuflolawsuit. For additional information, and to arrange for a free case review, please call 800-511-5092.
*star-telegram.com/2014/06/28/5935385/louisiana-sues-dialysis-drug-maker.html, The Associated Press, June 28, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP